Clinical trials: Toripalimab, completed
HCC, Therapy Adverse Effect
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Immunotherapy has become the main treatment recommendation for HCC. MWA treatment induces peripheral immune response, which may enhance the effectiveness of immunotherapy for advanced HCC.
- Trial name
- IMI-aHCC (NCT06581497)
- Testing
- ICIs, ICIs+MWA
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The First People's Hospital of Neijiang
Breast Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with triple negative breast cancer who have failed in routine systemic treatment.
- Trial name
- NCT02838823
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced/Metastatic Solid Tumors
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
- Trial name
- NCT04645069
- Testing
- ADG126 Mono, ADG126-anti PD1, ADG126-ADG106
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 58 people
- Sponsor
- Adagene Inc
Advanced Biliary Tract Cancer
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma.
- Trial name
- NCT04217954
- Testing
- OXA, 5-FU and bevacizumab plus Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking University
Carcinoma, Hepatocellular, Liver Neoplasms
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein…
- Conditions
- Carcinoma, Hepatocellular, Liver Neoplasms, Sintilimab, Portal Vein Tumor Thrombus
- Trial name
- NCT04618367
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors.
- Trial name
- NCT06139211
- Testing
- JS015, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD…
- Trial name
- NCT05830539
- Testing
- IN10018+PLD, IN10018+PLD+Toripalimab
- Where
- 7 sites in China
- Volunteers
- 68 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Head and Neck Squamous Cell Cancer
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
This study is a Phase Ib/II, open-label, multicenter clinical trial. Here, the study phase Ib is mainly to evaluate safety of combination regimen of Toripalimab and Cetuximab in treatment of relapsed or metastatic HNSCC failing…
- Trial name
- NCT04856631
- Testing
- Toripalimab Injection, Cetuximab Solution for infusion
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Esophageal Squamous Cell Carcinoma, Efficacy
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity
- Trial name
- NCT06281886
- Testing
- Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma (HCC)
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
This is a prospective, randomized, open-label, parallel-group, active controlled, multi-center phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab (hereafter referred to…
- Trial name
- NCT04723004
- Testing
- Toripalimab combined with Bevacizumab, Sorafenib
- Where
- 56 sites in China, Singapore
- Volunteers
- 326 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Stage II-III Non-small Cell Lung Cancer
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
This is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus…
- Trial name
- NCT04158440
- Testing
- 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- Where
- China
- Volunteers
- 501 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Penile Cancer
TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
- Trial name
- NCT06415318
- Testing
- Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Advanced Tumors
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
This is an open-label, dose-escalation and dose-expansion phase I clinical study to evaluate the safety and tolerability of JS006 as Monotherapy and in combination with toripalimab in patients with advanced tumors who have failed…
- Trial name
- NCT05061628
- Testing
- JS006 as Monotherapy, JS006 in combination with Toripalimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
For extensive-stage small cell lung cancer (SCLC), platinum-chemotherapy (cisplatin or carboplatin) combined with etoposide as the first-line treatment is recommended.
- Trial name
- NCT06648200
- Testing
- JS004, Toripalimab, Etoposide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma (HCC)
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The…
- Trial name
- NCT04605796
- Testing
- Toripalimab combined with Bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC.
- Trial name
- NCT04394975
- Testing
- Biological : Toripalimab Drug: Axitinib, sunitinib
- Where
- China
- Volunteers
- 421 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Lung Cancer
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with…
- Trial name
- NCT05664971
- Testing
- Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.